Selective EP4 Antagonists for Arthritis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoarthritis and rheumatoid arthritis, such as NSAIDs and COX-2 inhibitors, often come with cardiovascular side effects, limiting their use for patients with poor cardiovascular profiles, and there is a need for alternative therapies that effectively address joint inflammatory pain without these side effects.
Innovation Solution
Development of novel dimethyl-benzoic acid compounds that act as selective EP4 antagonists, which target the primary receptor involved in joint inflammatory pain, potentially reducing cardiovascular and gastrointestinal side effects compared to traditional treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NSAIDs or COX-2 inhibitors are used to treat arthritis, then anti-inflammatory and pain relief effects are achieved, but cardiovascular side effects occur
Solution Approach 1:
The invention segments the prostaglandin receptor system by developing selective EP4 antagonists that specifically target the EP4 receptor subtype while sparing other prostaglandin receptors and COX enzymes. This selective segmentation allows anti-inflammatory effects through EP4 blockade without the cardiovascular side effects associated with broad COX inhibition
Solution Approach 2:
The patent applies local quality by creating compounds with specific molecular structures (dimethyl-benzoic acid derivatives with particular substituent patterns) that confer selective affinity for the EP4 receptor. This localized molecular design ensures the drug acts specifically at the EP4 receptor site without affecting other prostaglandin pathways involved in cardiovascular homeostasis
2Object-affected harmful factors
If selective EP4 antagonists are developed to treat arthritis, then cardiovascular side effects are reduced, but the need for alternative mechanisms is required
Solution Approach 1:
The invention changes the pharmacological parameter from broad COX enzyme inhibition to selective EP4 receptor antagonism. By altering the target parameter from enzyme inhibition to receptor blockade, and from non-selective to subtype-selective action, the patent achieves cardiovascular safety while maintaining anti-inflammatory efficacy through a different mechanistic parameter
Data Source
AI summary
The present invention provides a compound of the Formula II: wherein A is: * R 1 is CH3, CF 3, or F; * R 2 is H, CH3, or F; * R 3 is CH3, OCH 3, OH, F; R 4 is OH or CH 20H; and * X is CH or N; These compounds are selective EP4 inhibitors and are useful for the treatment of inflammatory conditions such as arthritis.